Literature DB >> 22535015

Mastectomy without radiotherapy: outcome analysis after 10 years of follow-up in a single institution.

E Botteri1, O Gentilini, N Rotmensz, P Veronesi, S Ratini, C Fraga-Guedes, A Toesca, C Sangalli, A Del Castillo, M Rietjens, G Viale, R Orecchia, A Goldhirsch, U Veronesi.   

Abstract

The aim of this study was to identify the prognostic factors associated with the risk of loco-regional recurrence (LRR) of women undergoing mastectomy and complete axillary dissection without radiotherapy. We analyzed data from 650 women operated between 1997 and 2001 in a single institution. Median follow-up was 10 years. Overall survival was 89.8 % at 5 years and 76.6 % at 10 years. The 10-year cumulative incidence of LRRs was 10.0 % (5.0, 10.5, 15.8, and 18.5 % in patients with 0, 1-3, 4-9, and ≥10 positive lymph nodes (LNs), respectively). Sixty-two (9.5 %) LRRs were observed, 5 (0.8 %) of which occurred in the axillary LNs. Supraclavicular LNs recurrences (n = 16, 2.5 %) occurred more frequently in patients with four or more positive LNs, Ki-67 ≥ 20 % or extensive peritumoral vascular invasion (PVI). At multivariable analysis, nodal status was the only prognostic factor for local events, while nodal status, Ki-67 and PVI were significant prognostic factors for recurrences in the regional LNs. Moreover, within each category of positive LNs, high values of Ki-67 and extensive PVI were associated with the highest risk of LRR while low values of Ki-67 and absence of extensive PVI were associated with the lowest risk of LRR. Women with node-negative tumors have the lowest risk of LRR and represent the group of patients that might benefit the least from radiotherapy. PVI and Ki-67 might help tailoring PMRT indications among patients with positive LNs. Finally, the very low incidence of recurrences in the axillary LNs raises questions about the inclusion of the axilla in the radiation field.

Entities:  

Mesh:

Year:  2012        PMID: 22535015     DOI: 10.1007/s10549-012-2044-2

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  5 in total

1.  Robotic nipple-sparing mastectomy for the treatment of breast cancer: Feasibility and safety study.

Authors:  Antonio Toesca; Nickolas Peradze; Andrea Manconi; Viviana Galimberti; Mattia Intra; Marco Colleoni; Bernardo Bonanni; Giuseppe Curigliano; Mario Rietjens; Giuseppe Viale; Virgilio Sacchini; Paolo Veronesi
Journal:  Breast       Date:  2016-11-02       Impact factor: 4.380

2.  Most Breast Cancer Patients with T1-2 Tumors and One to Three Positive Lymph Nodes Do Not Need Postmastectomy Radiotherapy.

Authors:  Shirin Muhsen; Tracy-Ann Moo; Sujata Patil; Michelle Stempel; Simon Powell; Monica Morrow; Mahmoud El-Tamer
Journal:  Ann Surg Oncol       Date:  2018-03-21       Impact factor: 5.344

3.  A propensity score-matched analysis of breast-conserving surgery plus whole-breast irradiation versus mastectomy in breast cancer.

Authors:  Francesca Magnoni; Giovanni Corso; Patrick Maisonneuve; Giulia Massari; Luca Alberti; Giulia Castelnovo; Maria Cristina Leonardi; Virgilio Sacchini; Viviana Galimberti; Paolo Veronesi
Journal:  J Cancer Res Clin Oncol       Date:  2022-03-07       Impact factor: 4.553

4.  Breast cancer: post-mastectomy radiotherapy reduces recurrence and mortality.

Authors:  Roberto Orecchia
Journal:  Nat Rev Clin Oncol       Date:  2014-06-03       Impact factor: 66.675

5.  Postmastectomy Radiotherapy: An American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Focused Guideline Update.

Authors:  Abram Recht; Elizabeth A Comen; Richard E Fine; Gini F Fleming; Patricia H Hardenbergh; Alice Y Ho; Clifford A Hudis; E Shelley Hwang; Jeffrey J Kirshner; Monica Morrow; Kilian E Salerno; George W Sledge; Lawrence J Solin; Patricia A Spears; Timothy J Whelan; Mark R Somerfield; Stephen B Edge
Journal:  Ann Surg Oncol       Date:  2016-09-19       Impact factor: 5.344

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.